NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

TRAW

Traws Pharma Inc

Jul 01 • 04:00PM ET

1.46

Dollar change -0.02
Percentage change -1.35	%

Healthcare • Biotechnology • USA • NASD

Peers: JNJ PFE MRK BMY ABBV GILD VRTX LLY REGN AMGN

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-105.91	Insider Own	18.85%	Shs Outstand	5.08M	Perf Week	-4.58%
Market Cap	8.13M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	4.52M	Perf Month	2.82%
Enterprise Value	-7.81M	PEG	-	EPS next Q	-	Inst Own	20.34%	Short Float	7.91%	Perf Quarter	-36.52%
Income	-34.61M	P/S	35.34	EPS this Y	-	Inst Trans	0.56%	Short Ratio	0.31	Perf Half Y	-87.19%
Sales	0.23M	P/B	1.24	EPS next Y	-	ROA	-185.89%	Short Interest	0.36M	Perf YTD	-83.56%
Book/sh	1.18	P/C	0.51	EPS next 5Y	-	ROE	-576.08%	52W High	19.44 -92.49%	Perf Year	-87.02%
Cash/sh	2.86	P/FCF	-	EPS past 3/5Y	-13.62% 42.51%	ROIC	-576.80%	52W Low	0.97 50.52%	Perf 3Y	-90.87%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	0.00% -36.47%	Gross Margin	96.04%	Volatility	6.02% 11.19%	Perf 5Y	-98.66%
Dividend TTM	-	EV/Sales	-33.96	EPS Y/Y TTM	-389.86%	Oper. Margin	-21735.24%	ATR (14)	0.16	Perf 10Y	-100.00%
Dividend Ex-Date	-	Quick Ratio	1.81	Sales Y/Y TTM	0.44%	Profit Margin	-15245.81%	RSI (14)	44.59	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.81	EPS Q/Q	135.31%	SMA20	-10.10%	Beta	1.20	Target Price	6.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	1.79%	SMA50	-1.68%	Rel Volume	0.04	Prev Close	1.48
Employees	7	LT Debt/Eq	0.00	Earnings	May 15 BMO	SMA200	-66.24%	Avg Volume	1.17M	Price	1.46
IPO	Jul 25, 2013	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	46,659	Change	-1.35%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-01-22	Initiated	Ladenburg Thalmann	Buy	$7
May-18-21	Initiated	Guggenheim	Buy	$4
Mar-01-18	Reiterated	H.C. Wainwright	Buy	$6 → $7.50
Jan-17-18	Downgrade	Maxim Group	Buy → Hold
Oct-09-17	Initiated	H.C. Wainwright	Buy	$6
Apr-27-17	Initiated	Laidlaw	Buy	$10
Jul-01-15	Upgrade	Piper Jaffray	Neutral → Overweight
May-05-15	Initiated	H.C. Wainwright	Buy	$6

Jun-30-25 06:30AM	Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions (GlobeNewswire)
Jun-03-25 07:00AM	Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib (GlobeNewswire) +31.69%
May-27-25 08:00AM	Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness (GlobeNewswire) +6.87%
May-15-25 07:00AM	Traws Pharma Reports First Quarter 2025 Results and Business Highlights (GlobeNewswire) -11.29%
Apr-01-25 08:50PM	Traws Pharma, Inc. (TRAW) Virtual Investor Event Transcript (Seeking Alpha) -6.96% +8.41%
09:00AM	Loading…
Mar-31-25 09:00AM	Traws Pharma Reports Full Year 2024 Results and Business Highlights (GlobeNewswire)
Mar-28-25 04:30PM	Traws Pharma Announces Management Updates (GlobeNewswire) -6.61%
Mar-26-25 07:30AM	Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET (GlobeNewswire)
Mar-25-25 07:30AM	Traws Pharma's COVID-19 Candidate, Ratutrelvir, Presented at ICAR (GlobeNewswire) -6.69%
Mar-24-25 07:00AM	Traws Pharma Antiviral Bird Flu Program, Tivoxavir Marboxil, Shows Positive Data in Non-human Primates (GlobeNewswire)
Mar-21-25 07:00AM	Traws Pharma's Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR (GlobeNewswire)
Mar-03-25 07:00AM	Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil (GlobeNewswire) -30.82%
Feb-28-25 07:00AM	Traws Pharma Regains Compliance with NASDAQ Equity Listing Rule (GlobeNewswire)
Jan-23-25 07:00AM	Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu (PR Newswire) +12.24%
Jan-10-25 05:55PM	Expert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral Program (PR Newswire) -9.06%
08:00AM	Loading…
Dec-30-24 08:00AM	Traws Pharma, Inc. Announces Financing up to $72.6 Million from Leading Healthcare Institutional Investors to Advance Tivoxavir Marboxil Development for H5N1 Bird Flu to Approval (PR Newswire) -37.26%
Dec-23-24 07:00AM	Traws Pharma Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu (PR Newswire) +150.40%
Nov-14-24 04:30PM	Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results (GlobeNewswire) -10.59%
Oct-10-24 01:28PM	Expert Systems Celebrates Milestone in Clinical Development of Tivoxavir Marboxil, Potential One-Time Influenza Treatment (PR Newswire)
Oct-08-24 07:30AM	Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil (GlobeNewswire) -8.40%
Sep-30-24 07:30AM	Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor (GlobeNewswire)
Sep-23-24 09:37PM	Orbimed Advisors LLC Reduces Stake in Traws Pharma Inc (GuruFocus.com) +5.56%
09:48AM	Upcoming Stock Splits This Week (September 23 to September 27) Stay Invested (TipRanks)
Sep-20-24 07:30AM	Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors (GlobeNewswire) -8.32%
Sep-17-24 04:05PM	Traws Pharma, Inc. Announces Special Shareholders Meeting Results (GlobeNewswire) -10.26%
Aug-15-24 07:00AM	Traws Pharma Reports Q2 2024 Financial Results, Provides Recent Business Highlights (GlobeNewswire)
Aug-14-24 04:30PM	Traws Pharma to Host Corporate Update Call on August 15, 2024, at 8:00 AM ET (GlobeNewswire) -7.25%
May-23-24 08:00AM	Traws Pharma's ICAR Poster Highlights Potency of COVID-19 Candidate (GlobeNewswire)
May-16-24 09:29AM	Traws Pharma Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-07-24 08:00AM	Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy (GlobeNewswire)
07:15AM	Loading…
Apr-02-24 07:15AM	Traws Pharma Announces New Employee Inducement Grants (GlobeNewswire)
07:00AM	Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company (GlobeNewswire)
Mar-08-24 08:00AM	Onconova Therapeutics' Rigosertib Poster Selected for AACR 2024 (GlobeNewswire)
Dec-12-23 08:00AM	Onconova Therapeutics' Narazaciclib ASH Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma (GlobeNewswire) -10.63%
Dec-08-23 04:05PM	Onconova Therapeutics' Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i's (GlobeNewswire) +25.10%
Nov-28-23 08:00AM	Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets' Nineteenth Annual Emerging Growth Equity Conference (GlobeNewswire)
Nov-16-23 08:44AM	Onconova Therapeutics, Inc. (NASDAQ:ONTX) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-14-23 04:05PM	Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-07-23 04:05PM	Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023 (GlobeNewswire)
Nov-02-23 10:37AM	Onconova Therapeutics' ASH Poster To Focus on Narazaciclib in MCL (GlobeNewswire)
Oct-26-23 08:52PM	Lab Notes: Philadelphia health care investment firm closes two funds valued at over $500M (American City Business Journals)
Oct-24-23 08:00AM	Onconova Expands Leadership Team with Two Key Appointments (GlobeNewswire)
Oct-19-23 08:00AM	Promising Preclinical Narazaciclib Data Presented at MCL Meeting (GlobeNewswire)
Oct-12-23 08:00AM	Encouraging Rigosertib Data Presented at EADV as Late Breaker (GlobeNewswire)
Sep-28-23 08:00AM	Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress (GlobeNewswire)
Sep-06-23 08:00AM	Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-13-23 05:36AM	Onconova Therapeutics, Inc. (NASDAQ:ONTX) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-11-23 07:57AM	Q2 2023 Onconova Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -5.87%
Aug-10-23 04:05PM	Onconova Therapeutics Reports Corporate Update and Announces Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-03-23 04:05PM	Onconova Therapeutics to Provide Corporate Update and Announce Second Quarter 2023 Financial Results on August 10, 2023 (GlobeNewswire)
Jul-17-23 06:59AM	Here's Why We're Watching Onconova Therapeutics' (NASDAQ:ONTX) Cash Burn Situation (Simply Wall St.)
Jun-14-23 08:00AM	Onconova Therapeutics Presents Preclinical Data on Narazaciclib at the 17th International Conference on Malignant Lymphoma (GlobeNewswire)
Jun-05-23 08:00AM	Onconova Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology Annual Meeting (GlobeNewswire)
May-25-23 08:00AM	Onconova Therapeutics Announces Dosing of First Participant in Investigator-Sponsored Phase 2 Trial of Rigosertib Plus Pembrolizumab in Metastatic Melanoma Patients Refractory to Immune Checkpoint Blockade (GlobeNewswire)
May-16-23 06:29AM	Q1 2023 Onconova Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
May-15-23 05:35PM	Onconova Therapeutics, Inc. (ONTX) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -5.60%
04:18PM	Onconova Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
May-12-23 08:00AM	Onconova Therapeutics to Participate in Ladenburg Thalmann Virtual R&D Showcase on Narazaciclib in Endometrial Cancer (GlobeNewswire) +5.04%
May-11-23 08:00AM	Onconova Therapeutics Doses First Patient in Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer (GlobeNewswire) -8.46%
May-08-23 08:00AM	Onconova Therapeutics to Present at the ISID International Epidermolysis Bullosa Symposium (GlobeNewswire)
May-04-23 04:05PM	Onconova Therapeutics to Provide Corporate Update and Announce First Quarter 2023 Financial Results on May 15, 2023 (GlobeNewswire) -6.47% +7.69%
Apr-19-23 09:00AM	Onconova Therapeutics Announces the Presentation of New Preclinical Data on Narazaciclib at the AACR Annual Meeting (GlobeNewswire)
Apr-06-23 04:05PM	Onconova Therapeutics Announces the Unexpected Passing of Chief Medical Officer Dr. Mark Gelder (GlobeNewswire)
Mar-23-23 08:00AM	Onconova Therapeutics and Pangea Biomed Enter into Research Collaboration to Identify Biomarkers of Response to Rigosertib (GlobeNewswire)
Mar-18-23 02:06AM	Onconova Therapeutics, Inc. (NASDAQ:ONTX) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-17-23 06:17AM	Q4 2022 Onconova Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-16-23 04:04PM	Onconova Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire) +7.09%
Mar-15-23 08:00AM	Onconova Therapeutics Announces Upcoming Poster Presentations at the AACR Annual Meeting (GlobeNewswire)
Mar-09-23 04:05PM	Onconova Therapeutics to Provide Corporate Update and Announce Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023 (GlobeNewswire)
Mar-07-23 08:00AM	Onconova Therapeutics Presents Preclinical Data Characterizing Rigosertibs Mechanisms of Action at the AACR Targeting RAS Conference (GlobeNewswire)
Feb-07-23 11:16AM	Onconova Therapeutics Touts Additional Positive Data For Rigosertib Monotherapy In Skin Cancer Setting (Benzinga) +13.56%
08:00AM	Onconova Therapeutics Announces Additional Clinical Data Demonstrating Rigosertibs Monotherapy Activity in RDEB-Associated Squamous Cell Carcinoma (GlobeNewswire)
Feb-06-23 10:09AM	We Think Onconova Therapeutics (NASDAQ:ONTX) Needs To Drive Business Growth Carefully (Simply Wall St.)
Feb-01-23 08:00AM	Onconova Therapeutics to Present at the 2023 Guggenheim Oncology Conference (GlobeNewswire) +13.60%
Jan-26-23 08:00AM	Onconova Therapeutics Announces Participation in the Channelchek Takeaway Series (GlobeNewswire)
Dec-19-22 04:05PM	Onconova Therapeutics Appoints Drs. Peter Atadja and Trafford Clarke to its Board of Directors (GlobeNewswire) -7.13%
Dec-07-22 08:00AM	Onconova Therapeutics to Present at the Upcoming MedInvest Oncology Investor Conference (GlobeNewswire) -6.22%
Nov-28-22 08:00AM	Onconova Therapeutics to Present at the Upcoming RHK Capital Disruptive Growth Conference (GlobeNewswire)
Nov-17-22 05:29AM	Onconova Therapeutics Third Quarter 2022 Earnings: Misses Expectations (Simply Wall St.)
Nov-14-22 05:25PM	Onconova Therapeutics, Inc. (ONTX) Reports Q3 Loss, Misses Revenue Estimates (Zacks) +23.09%
04:05PM	Onconova Therapeutics Announces Plans for a Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer, Reports Third Quarter 2022 Financial Results, and Provides a Business Update (GlobeNewswire)
Nov-07-22 04:05PM	Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter Financial Results on November 14, 2022 (GlobeNewswire)
Sep-22-22 08:00AM	Onconova Therapeutics to Present at the Ladenburg Thalmann 2022 Healthcare Conference (GlobeNewswire) -6.14%
Sep-12-22 08:00AM	Onconova Therapeutics Announces Updated Data from Investigator-sponsored Phase 1/2a Trial Evaluating Rigosertib in Combination with Nivolumab in Advanced KRAS-mutated Non-Small Cell Lung Cancer at the ESMO Congress 2022 (GlobeNewswire)
Sep-01-22 08:00AM	Onconova Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-11-22 05:25PM	Onconova Therapeutics, Inc. (ONTX) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Onconova Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Aug-04-22 06:35PM	Profound Medical (PROF) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +15.08%
04:05PM	Onconova Therapeutics to Provide Corporate Update and Announce Second Quarter Financial Results on August 11, 2022 (GlobeNewswire)
Jun-13-22 08:00AM	Onconova Therapeutics Announces Key Management Promotions (GlobeNewswire) -12.03%
May-26-22 05:10PM	Onconova Therapeutics Announces Abstract at the ASCO Annual Meeting Highlighting Narazaciclibs Differentiated Inhibitory and Improved Safety Profile in Preclinical Models (GlobeNewswire)
May-15-22 08:04AM	Is Onconova Therapeutics (NASDAQ:ONTX) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
May-12-22 10:20AM	Regulus (RGLS) Up as FDA Accepts IND for Kidney Disease Drug (Zacks)
May-11-22 04:05PM	Onconova Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) -8.86%
11:20AM	Catalyst Pharmaceuticals (CPRX) Q1 Earnings Miss, Revenues Up Y/Y (Zacks)
May-10-22 05:55PM	Collegium Pharmaceutical (COLL) Lags Q1 Earnings Estimates (Zacks)
May-09-22 06:45PM	Heron Therapeutics (HRTX) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -10.00%
May-05-22 07:15PM	Theravance Biopharma (TBPH) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -5.11%
May-04-22 04:05PM	Onconova Therapeutics to Provide Corporate Update and Announce First Quarter Financial Results on May 11, 2022 (GlobeNewswire)
May-03-22 01:00PM	Onconova (ONTX) to Report Q1 Earnings: What's in the Cards? (Zacks)

Traws Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
CAUTREELS WERNER	Chief Executive Officer	Feb 18 '25	Option Exercise	0.01	96,348	963	104,348	Feb 19 06:23 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TRAW

Traws Pharma Inc

Upgrade your FINVIZ experience